Details of the Drug | DrugMAP

General Information of Drug (ID: DMZ3HD1)

Drug Name

SC-002

Synonyms

SC-004

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Phase 1	[1]
Small-cell lung cancer	2C25.Y	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C15H12N8O5S3
Canonical SMILES: C1C(=C(N2C(S1)C(C2=O)C(=O)NC(=NO)C3=NSC(=N3)N)C(=O)O)C=CC4=CSN=N4
InChI: 1S/C15H12N8O5S3/c16-15-18-10(21-31-15)9(20-28)17-11(24)7-12(25)23-8(14(26)27)5(3-29-13(7)23)1-2-6-4-30-22-19-6/h1-2,4,7,13,28H,3H2,(H,26,27)(H2,16,18,21)(H,17,20,24)/b2-1+/t7?,13-/m1/s1
InChIKey: HFOMCBOZKJQJHK-CLIAQYSASA-N

Cross-matching ID

PubChem CID: 136693871
TTD ID: D0D4OL

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT02500914) SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)